TEANECK, N.J., July 21, 2020 /PRNewswire/
-- Cognizant (Nasdaq: CTSH) announced that its
Shared Investigator Platform (SIP), a life sciences Software as a
Service (SaaS) solution, has reached a new milestone of over
100,000 users in 84 countries. The platform has become increasingly
critical to progressing clinical trials as prevailing social
distancing norms have significantly curtailed in-person
collaboration. Many of the companies utilizing the Shared
Investigator Platform are working to accelerate COVID-19 therapies
through virtual clinical trial processes.
The Shared Investigator Platform, in use by 7 of the
largest global biopharmaceutical companies, links clinical trial
sponsors and medical professionals by leveraging automation and
remote access technology to increase the speed and efficiency of
administering drug trials and bringing new therapies to market. The
platform was first launched in 2016 as part of a collaboration
between Cognizant and TransCelerate, a consortium of the world's
largest biopharmaceutical organizations. These industry leaders
collaboratively standardized clinical trial documents, training and
start-up activities into a single shared environment to reduce
costs and increase efficiency.
Today, the Cognizant platform is used at over 19,000 trial-ready
sites by medical and life sciences professionals to reduce
administrative burdens that often slow the development and testing
of life-saving clinical therapies. A global biopharmaceutical
company using the platform realized a 50% reduction in critical
site activation cycle time, based on an internal sponsor benchmark
study.
"The COVID-19 pandemic has brought the processes of healthcare
and life sciences firms to the forefront of global attention as the
need to leverage advanced technologies for faster results and
better care is paramount," said Srinivas Shankar, Senior Vice
President and Global Head for Cognizant's Life Sciences
business. "Our Shared Investigator Platform seamlessly enables
communication and collaboration in clinical trials in areas such as
site activation, document exchange, and safety notifications. Our
milestone of 100,000 users across 84 countries is a testament to
the value we are providing to those diligently working to
accelerate innovative, effective treatments to patients in
need."
Learn more about Cognizant's Shared Investigator
Platform: https://www.cognizant.com/shared-investigator-platform
About Cognizant
Cognizant (Nasdaq: CTSH) is one of the world's leading
professional services companies, transforming clients' business,
operating and technology models for the digital era. Our unique
industry-based, consultative approach helps clients envision, build
and run more innovative and efficient businesses. Headquartered in
the U.S., Cognizant is ranked 194 on the Fortune 500 and is
consistently listed among the most admired companies in the world.
Learn how Cognizant helps clients lead with digital
at www.cognizant.com or follow us @Cognizant.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cognizant-shared-investigator-platform-for-life-sciences-reaches-major-milestone-in-accelerating-drug-discovery-301096354.html
SOURCE Cognizant